The estimated six-year survival price was 44.2% with ribociclib, in contrast with 32% for placebo. Gabriel Hortobagyi, M.D., professor of Breast Medical Oncology, introduced the findings on the digital European Society for Medical Oncology (ESMO) Congress 2021.
“These findings build on previous MONALEESA trials that achieved a survival benefit with the addition of ribociclib,” mentioned Hortobagyi.
“I am very encouraged that metastatic breast cancer patients may have a treatment option that extends survival, delays chemotherapy treatment and preserves their quality of life.”
Previously examine proven ribociclib and letrozole improved progression-free survival of postmenopausal ladies with HR+ metastatic breast most cancers within the MONALEESA-2 trial.
The worldwide double-blind examine, MONALEESA-2, enrolled 668 postmenopausal ladies with superior breast most cancers at 223 trial websites in 29 international locations. They had been randomized to obtain both ribociclib and letrozole, or letrozole and placebo. None had been beforehand handled for his or her superior illness. Trial individuals had been 82.2% white, 7.6% Asian, 2.5% Black and seven.6% different.
The median follow-up was 79.7 months, and the time to first chemotherapy remedy was 50.6 months for sufferers who acquired ribociclib, in comparison with 38.9 months for placebo.
No new security alerts had been noticed, and opposed occasions had been per earlier reported Phase III MONALEESA trial outcomes.
“Given these results, the combination of a CDK4/6 inhibitor plus an aromatase inhibitor should be the standard first-line treatment for the majority of patients with advanced hormone receptor-positive breast cancer,” mentioned Hortobagyi. “These findings have the potential to impact most women diagnosed with metastatic breast cancer.”
The examine was sponsored by Novartis Pharmaceuticals Corporation, which markets ribociclib (Kisqali). Hortobagyi serves as a paid advisor for Novartis, and MD Anderson acquired funds from Novartis to conduct this examine. A full checklist of collaborating researchers and their disclosures are included within the summary.